Cerevance reports positive Phase 3 Arise results for once-daily solengepras in Parkinson's
61 hours vs placebo at week 12, and showed motor and non-motor benefits; adverse-event discontinuation was 3.5%, same as placebo.
5%, Same As Placebo * CEREVANCE: TO MEET WITH FDA TO DISCUSS PATH TO POTENTIAL New Drug Application For Solengepras Source text:... com;)